Gavestinel Sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529421

CAS#: 153436-38-5 (sodium)

Description: Gavestinel Sodium is an NMDA glycine-site antagonist potentially for the treatment of stroke.

Chemical Structure

Gavestinel Sodium
CAS# 153436-38-5 (sodium)

Theoretical Analysis

MedKoo Cat#: 529421
Name: Gavestinel Sodium
CAS#: 153436-38-5 (sodium)
Chemical Formula: C18H11Cl2N2NaO3
Exact Mass: 0.00
Molecular Weight: 397.180
Elemental Analysis: C, 54.43; H, 2.79; Cl, 17.85; N, 7.05; Na, 5.79; O, 12.08

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 153436-22-7 (free base)   153436-38-5 (sodium),  

Synonym: GV-150526A; GV150526A; GV 150526A

IUPAC/Chemical Name: sodium (E)-4,6-dichloro-3-(3-oxo-3-(phenylamino)prop-1-en-1-yl)-1H-indole-2-carboxylate


InChi Code: InChI=1S/C18H12Cl2N2O3.Na/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11;/h1-9,22H,(H,21,23)(H,24,25);/q;+1/p-1/b7-6+;

SMILES Code: O=C(C(N1)=C(/C=C/C(NC2=CC=CC=C2)=O)C3=C1C=C(Cl)C=C3Cl)[O-].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 397.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Martin-Flores M, Cheetham J, Campoy L, Sakai DM, Heerdt PM, Gleed RD. Effect of gantacurium on evoked laryngospasm and duration of apnea in anesthetized healthy cats. Am J Vet Res. 2015 Mar;76(3):216-23. doi: 10.2460/ajvr.76.3.216. PubMed PMID: 25710757.

2: Sunaga H, Zhang Y, Savarese JJ, Emala CW. Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology. 2010 Apr;112(4):892-9. doi: 10.1097/ALN.0b013e3181d32016. PubMed PMID: 20216393; PubMed Central PMCID: PMC2854830.

3: Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM. Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology. 2010 Jul;113(1):58-73. doi: 10.1097/ALN.0b013e3181dc1b5b. PubMed PMID: 20526187.

4: Naguib M, Brull SJ. Update on neuromuscular pharmacology. Curr Opin Anaesthesiol. 2009 Aug;22(4):483-90. doi: 10.1097/ACO.0b013e32832b8cff. Review. PubMed PMID: 19384229.

5: Heerdt PM, Sunaga H, Savarese JJ. Novel neuromuscular blocking drugs and antagonists. Curr Opin Anaesthesiol. 2015 Aug;28(4):403-10. doi: 10.1097/ACO.0000000000000209. Review. PubMed PMID: 26087274.

6: Prabhakar A, Kaye AD, Wyche MQ, Salinas OJ, Mancuso K, Urman RD. Novel drug development for neuromuscular blockade. J Anaesthesiol Clin Pharmacol. 2016 Jul-Sep;32(3):376-8. doi: 10.4103/0970-9185.188833. PubMed PMID: 27625489; PubMed Central PMCID: PMC5009847.

7: Lien CA. Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents. Br J Anaesth. 2011 Dec;107 Suppl 1:i60-71. doi: 10.1093/bja/aer341. Review. PubMed PMID: 22156271.

8: Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care. 2009 Mar;24(1):50-7. doi: 10.1016/j.jcrc.2008.11.001. Review. PubMed PMID: 19272539.

9: Lien CA, Belmont MR, Heerdt PM. GW280430A: pharmacodynamics and potential adverse effects. Anesthesiology. 2005 Apr;102(4):861-2; author reply 862-3. PubMed PMID: 15791118.

10: Gyermek L. Development of ultra short-acting muscle relaxant agents: history, research strategies, and challenges. Med Res Rev. 2005 Nov;25(6):610-54. Review. PubMed PMID: 16086361.

11: Savarese JJ, Belmont MR, Hashim MA, Mook RA Jr, Boros EE, Samano V, Patel SS, Feldman PL, Schultz JA, McNulty M, Spitzer T, Cohn DL, Morgan P, Wastila WB. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium. Anesthesiology. 2004 Apr;100(4):835-45. PubMed PMID: 15087618.

12: Geldner GF, Blobner M. GW280430A. Anesthesiology. 2005 Apr;102(4):861; author reply 862-5. PubMed PMID: 15791119.

13: Heerdt PM, Kang R, The' A, Hashim M, Mook RJ Jr, Savarese JJ. Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology. 2004 Apr;100(4):846-51. PubMed PMID: 15087619.

14: Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ. Clinical pharmacology of GW280430A in humans. Anesthesiology. 2004 Apr;100(4):768-73. PubMed PMID: 15087609.

15: Caldwell JE. The continuing search for a succinylcholine replacement. Anesthesiology. 2004 Apr;100(4):763-4. PubMed PMID: 15087607.

16: Zhu H, Meserve K, Floyd A. Preformulation studies for an ultrashort-acting neuromuscular blocking agent GW280430A. I. Buffer and cosolvent effects on the solution stability. Drug Dev Ind Pharm. 2002;28(2):135-42. PubMed PMID: 11926357.

17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jan-Feb;27(1):49-77. PubMed PMID: 15834459.

18: Zhu HJ, Sacchetti M. Solid state characterization of an neuromuscular blocking agent--GW280430A. Int J Pharm. 2002 Mar 2;234(1-2):19-23. PubMed PMID: 11839434.